These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 451484)

  • 21. Pseudomonas aeruginosa vaccine in cancer patients.
    Young LS; Meyer RD; Armstrong D
    Ann Intern Med; 1973 Oct; 79(4):518-27. PubMed ID: 4201225
    [No Abstract]   [Full Text] [Related]  

  • 22. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
    Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
    APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection.
    Okada K; Kawaharajo K; Kasai T; Homma JY
    Jpn J Exp Med; 1980 Feb; 50(1):53-61. PubMed ID: 6770131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection.
    Lang AB; Rüdeberg A; Schöni MH; Que JU; Fürer E; Schaad UB
    Pediatr Infect Dis J; 2004 Jun; 23(6):504-10. PubMed ID: 15194830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
    Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
    Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine.
    Jones RJ
    J Hyg (Lond); 1979 Jun; 82(3):453-62. PubMed ID: 109501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccines against Pseudomonas aeruginosa infection: 2. Clinico-immunological investigations.
    Krokhina MA; Grishina IA; Panova YuM ; Terekhova RP; Severtsova MK; Yedvabnaya LS; Vaide M; Varro R; Rusanov VM; Kolker II
    Vaccine; 1985 Sep; 3(3):316-24. PubMed ID: 3933202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A reduction of Pseudomonas septicemias in burned patients by the immune process.
    Pierson C; Feller I
    Surg Clin North Am; 1970 Dec; 50(6):1377-83. PubMed ID: 4922825
    [No Abstract]   [Full Text] [Related]  

  • 29. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia.
    Naito Y; Hamaoka S; Kinoshita M; Kainuma A; Shimizu M; Katoh H; Moriyama K; Ishii KJ; Sawa T
    Microbiol Immunol; 2018 Dec; 62(12):774-785. PubMed ID: 30378708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa.
    Golpasha ID; Mousavi SF; Owlia P; Siadat SD; Irani S
    Bosn J Basic Med Sci; 2015 May; 15(2):15-24. PubMed ID: 26042508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Use of a vaccine for prevention of Pseudomonas aeruginosa infection of burn wounds in mice].
    Grochowski J; Bilinska M; Stankiewicz D; Arkusiewicz E
    Pol Przegl Chir; 1979 Jun; 51(6):623-7. PubMed ID: 116210
    [No Abstract]   [Full Text] [Related]  

  • 32. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization.
    Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ
    Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection.
    Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G
    Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new Pseudomonas vaccine: preliminary trial on human volunteers.
    Jones RJ; Roe EA; Lowbury EJ; Miler JJ; Spilsbury JF
    J Hyg (Lond); 1976 Jun; 76(3):429-39. PubMed ID: 819576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination for Pseudomonas aeruginosa.
    Alexander JW; Fisher MW
    Am J Surg; 1970 Oct; 120(4):512. PubMed ID: 4990276
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunological control of Pseudomonas infection in burn patients: a clinical evaluation.
    Alexander JW; Fisher MW; MacMillan BG
    Arch Surg; 1971 Jan; 102(1):31-5. PubMed ID: 4992359
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunological control of pseudomonas infection in burns.
    R I Med J; 1972 Mar; 55(3):88. PubMed ID: 4622683
    [No Abstract]   [Full Text] [Related]  

  • 38. [Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin].
    Moroz AF; Kharitonova AM; Chanturiia TsK
    Antibiotiki; 1983 May; 28(5):341-5. PubMed ID: 6410985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoprophylaxis of Pseudomonas aeruginosa.
    Young LS; Armstrong D; Markley K
    Ann Intern Med; 1971 Jun; 74(6):1012-3. PubMed ID: 4996343
    [No Abstract]   [Full Text] [Related]  

  • 40. Active immunization of burned patients with a new multivalent Staphylococcus-Pseudomonas vaccine.
    Sachs A
    Prog Immunobiol Stand; 1971; 5():428-32. PubMed ID: 4633971
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.